Patents by Inventor Mitchell P. Fink
Mitchell P. Fink has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7528174Abstract: Compositions and methods are disclosed for treating an illness that is caused or associated with cellular damage or dysfunction which is caused by excessive mitochondrial production of reaction oxygen species (ROS). Compositions which act as mitochondria-selective targeting agents using specific structural signaling features recognizable by cells as mitochondrial targeting sequences are discussed. A method for delivering these agents effectively into cells and mitochondria where they act as electron scavengers by way of certain targeting sequences is also disclosed. Mitochondria dysfunction and cell death by way of apoptosis is inhibited as a result of the ROS-scavenging activity, thereby increasing the survival rate of the patient. In a preferred embodiment, the compositions and methods may be administered therapeutically in the field to patients with profound hemorrhagic shock so that survival could be prolonged until it is feasible to obtain surgical control of the bleeding vessels.Type: GrantFiled: August 17, 2006Date of Patent: May 5, 2009Assignee: University of Pittsburgh-Of The Commonwealth System of Higher EducationInventors: Peter Wipf, Jingbo Xiao, Mitchell P. Fink, Valerian E. Kagan, Yulia Y. Tyurina
-
Publication number: 20090042808Abstract: Provided herein are methods for using mitochondria-targeted electron scavengers as anti-inflammatory agents. The mitochondria-targeted electron scavenger comprises a free radical-scavenging group covalently linked to a mitochondria-targeting group derived from a hemigramicidin moiety. The mitochondria-targeted electron scavenger can be used to treat medical conditions associated with acute or chronic inflammation.Type: ApplicationFiled: August 8, 2008Publication date: February 12, 2009Inventors: Mitchell P. Fink, Peter Wipf
-
Publication number: 20080214454Abstract: Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise a vertebrate HMGB A box, and an antibody preparation that specifically binds to a vertebrate HMGB B box. The methods comprise treating a cell or a patient with sufficient amounts of the composition to inhibit the release of the proinflammatory cytokine, or to inhibit the inflammatory cytokine cascade.Type: ApplicationFiled: September 19, 2007Publication date: September 4, 2008Inventors: Kevin J. Tracey, Huan Yang, Howland Shaw Warren, Mitchell P. Fink
-
Publication number: 20080167234Abstract: Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise a vertebrate HMGB A box, and an antibody preparation that specifically binds to a vertebrate HMGB B box. The methods comprise treating a cell or a patient with sufficient amounts of the composition to inhibit the release of the proinflammatory cytokine, or to inhibit the inflammatory cytokine cascade.Type: ApplicationFiled: September 19, 2007Publication date: July 10, 2008Inventors: Kevin J. Tracey, Huan Yang, Howland Shaw Warren, Mitchell P. Fink
-
Patent number: 7332479Abstract: A method of prophylaxis or treatment of inflammatory conditions, including, but not limited to, intestinal epithelial inflammation due to intestine-specific conditions (e.g., Crohn's disease or ulcerative colitis) or systemic causes of inflammation (e.g., endotoxemia, sepsis, hemorrhagic shock/resuscitation or pancreatitis) is disclosed. In the method of the invention, an affected patient is administered a therapeutically effective amount of a composition including an NAD-related compound, in a form that is accessible to a receptor molecule, conveyed in a pharmaceutically acceptable carrier vehicle. NAD-related compounds include nicotinamide adenine dinucleotide (NAD+), cyclic adenosine diphosphate ribose (cADPR), or functionally equivalent analogues, derivatives, metabolites or agonists thereof or prodrugs therefor.Type: GrantFiled: September 10, 2003Date of Patent: February 19, 2008Assignee: University of Pittsburgh - of the Commonwealth System of Higher EducationInventors: Mitchell P. Fink, Russell L. Delude, Xianonan Han
-
Patent number: 7304034Abstract: Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise a vertebrate HMGB A box, and an antibody preparation that specifically binds to a vertebrate HMGB B box. The methods comprise treating a cell or a patient with sufficient amounts of the composition to inhibit the release of the proinflammatory cytokine, or to inhibit the inflammatory cytokine cascade.Type: GrantFiled: November 20, 2002Date of Patent: December 4, 2007Assignees: The Feinstein Institute for Medical Research, The General Hospital Corporation, University of Pittsburgh-Of the Commonwealth System of Higher EducationInventors: Kevin J. Tracey, Huan Yang, Howland Shaw Warren, Jr., Mitchell P. Fink
-
Publication number: 20070161544Abstract: The present invention relates to compositions and methods for providing mitochondria-selective targeting agents covalently linked to desired cargo such as radical scavenging agents. Compositions and methods are disclosed for treating an illness that is caused or associated with cellular damage or dysfunction which is caused by excessive mitochondrial production of reaction oxygen species (ROS). Compositions which act as mitochondria-selective targeting agents using specific structural signaling features recognizable by cells as mitochondrial targeting sequences are discussed. A method for delivering these agents effectively into cells and mitochondria where they act as electron scavengers by way of certain targeting sequences is also disclosed. Mitochondria and cell death by way of apoptosis is inhibited as a result of the ROS-scavenging activity, thereby increasing the survival rate of the patient.Type: ApplicationFiled: August 18, 2006Publication date: July 12, 2007Inventors: Peter Wipf, Jingbo Xiao, Mitchell P. Fink, Valerian E. Kagan, Yulia Y. Tyurina, Anthony J. Kanai
-
Publication number: 20070161573Abstract: Compositions and methods are disclosed for treating an illness that is caused or associated with cellular damage or dysfunction which is caused by excessive mitochondrial production of reaction oxygen species (ROS). Compositions which act as mitochondria-selective targeting agents using specific structural signaling features recognizable by cells as mitochondrial targeting sequences are discussed. A method for delivering these agents effectively into cells and mitochondria where they act as electron scavengers by way of certain targeting sequences is also disclosed. Mitochondria dysfunction and cell death by way of apoptosis is inhibited as a result of the ROS-scavenging activity, thereby increasing the survival rate of the patient. In a preferred embodiment, the compositions and methods may be administered therapeutically in the field to patients with profound hemorrhagic shock so that survival could be prolonged until it is feasible to obtain surgical control of the bleeding vessels.Type: ApplicationFiled: August 17, 2006Publication date: July 12, 2007Inventors: Peter Wipf, Jingbo Xiao, Mitchell P. Fink, Valerian E. Kagan, Yulia Y. Tyurina
-
Patent number: 6943190Abstract: This invention is directed to a method of using a therapeutic composition comprising a compound of an alpha-ketoalkanoic acid (pyruvate) and/or its derivatives for the treatment of cytokine-mediated inflammatory conditions. The compound is an alpha-ketoalkanoic acid, a physiologically acceptable salt of an alpha-ketoalkanoic acid, an ester of an alpha-ketoalkanoic acid, or an amide of an alpha-ketoalkanoic acid. A component for inducing and stabilizing the enol resonance form of the ester at physiological pH values is also disclosed. The cytokine-mediated inflammatory conditions are mediated by, for example, an “early” (Tumor Necrosis Factor (TNF), interleukin-1? (IL-1?)) or “late” (high mobility group B-1 (HMGB-1)) mediator of inflammation.Type: GrantFiled: September 15, 2003Date of Patent: September 13, 2005Assignees: University of Pittsburgh-of the Commonwealth System of Higher Education, North Shore-Long Island Jewish Research InstituteInventors: Mitchell P. Fink, Luis Ulloa, Kevin J. Tracey, Russell L. Delude
-
Patent number: 6846842Abstract: A therapeutic composition comprising an alkyl, aralkyl, alkoxyalkyl or carboxyalkyl ester of 2-ketoalkanoic acid and a component for inducing and stabilizing the enol resonance form of the ester at physiological pH values is disclosed. The composition of the invention further comprises a pharmceutically acceptable carier vehicle in which the enol resonance form of the ester is stabilized at physiological pH values. Formulations containing the compositions of the invention permit the successful use of 2-ketoalkanoic acid esters, e.g., pyruvic acid esters, to treat, e.g., ischemic events, shock, organ reanimation, resuscitation and other recognized pyruvate-effective treatments. The compositions of the inventions are also useful in a process for preserving organ parts, organs or limbs removed from a living mammal and in need of preservation, e.g., for later transplantation to an organ recipient.Type: GrantFiled: April 4, 2002Date of Patent: January 25, 2005Assignees: Beth Israel Deconess Medical Center, Inc., Xanthus Life Sciences, Inc.Inventors: Alfred M. Ajami, Carrie A. Sims, Mitchell P. Fink
-
Publication number: 20040110833Abstract: This invention is directed to a method of using a therapeutic composition comprising a compound of an alpha-ketoalkanoic acid (pyruvate) and/or its derivatives for the treatment of cytokine-mediated inflammatory conditions. The compound is an alpha-ketoalkanoic acid, a physiologically acceptable salt of an alpha-ketoalkanoic acid, an ester of an alpha-ketoalkanoic acid, or an amide of an alpha-ketoalkanoic acid. A component for inducing and stabilizing the enol resonance form of the ester at physiological pH values is also disclosed. The cytokine-mediated inflammatory conditions are mediated by, for example, an “early” (Tumor Necrosis Factor (TNF), interleukin-1&bgr; (IL-1&bgr;)) or “late” (high mobility group B-1 (HMGB-1)) mediator of inflammation.Type: ApplicationFiled: September 15, 2003Publication date: June 10, 2004Applicants: University of Pittsburgh of the Commonwealth System of Higher Education, North Shore-Long Island Jewish Research InstituteInventors: Mitchell P. Fink, Luis Ulloa, Kevin J. Tracey
-
Publication number: 20040068006Abstract: Disclosed is a method of treating acute renal failure in a subject. The method comprises the step of administering to the subject an effective amount of a composition comprising a 2-ketoalkanoic acid, a pharmaceutically acceptable salt of a 2-ketoalkanoic acid, an ester of a 2-ketoalkanoic acid, or an amide of a 2-ketoalkanoic acid. Preferably, the composition comprises an enolization agent and an alkyl aralkyl, alkoxyalkyl or carboxyalkyl ester of a 2-ketoalkanoic acid dissolved in a pharmaceutically acceptable vehicle.Type: ApplicationFiled: October 3, 2003Publication date: April 8, 2004Applicant: Critical Therapeutics, Inc.Inventors: Mitchell P. Fink, Howland Shaw Warren
-
Publication number: 20030232884Abstract: Disclosed is a pharmaceutical composition comprising an ester of an alpha-ketoalkanoic acid or an amide of an alpha-ketoalkanoic and lactic acid or a pharmaceutically acceptable salt of lactic acid dissolved in aqueous solution.Type: ApplicationFiled: April 17, 2003Publication date: December 18, 2003Applicant: Critical Therapeutics, Inc.Inventor: Mitchell P. Fink
-
Publication number: 20030216470Abstract: Disclosed is a method for treating ileus in a subject. The method comprises the step of administering to the subject an effective amount of an alpha-ketoalkanoic acid, a physiologically-acceptable salt of an alpha-ketoalkanoic acid, an ester of an alpha-ketoalkanoic acid, or an amide of an alpha-ketoalkanoic acid.Type: ApplicationFiled: April 17, 2003Publication date: November 20, 2003Inventor: Mitchell P. Fink
-
Publication number: 20030144201Abstract: Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise a vertebrate HMGB A box, and an antibody preparation that specifically binds to a vertebrate HMGB B box. The methods comprise treating a cell or a patient with sufficient amounts of the composition to inhibit the release of the proinflammatory cytokine, or to inhibit the inflammatory cytokine cascade.Type: ApplicationFiled: November 20, 2002Publication date: July 31, 2003Applicant: North Shore-Long Island Jewish Research InstituteInventors: Kevin J. Tracey, Huan Yang, Howland Shaw Warren, Mitchell P. Fink
-
Publication number: 20030073743Abstract: A therapeutic composition comprising an alkyl, aralkyl, alkoxyalkyl or carboxyalkyl ester of 2-ketoalkanoic acid and a component for inducing and stabilizing the enol resonance form of the ester at physiological pH values is disclosed. The composition of the invention further comprises a pharmceutically acceptable carier vehicle in which the enol resonance form of the ester is stabilized at physiological pH values. Formulations containing the compositions of the invention permit the successful use of 2-ketoalkanoic acid esters, e.g., pyruvic acid esters, to treat, e.g., ischemic events, shock, organ reanimation, resuscitation and other recognized pyruvate-effective treatments. The compositions of the inventions are also useful in a process for preserving organ parts, organs or limbs removed from a living mammal and in need of preservation, e.g., for later transplantation to an organ recipient.Type: ApplicationFiled: April 4, 2002Publication date: April 17, 2003Applicant: Xanthus Life Sciences, Inc.Inventors: Alfred M. Ajami, Carrie A. Sims, Mitchell P. Fink
-
Publication number: 20030060410Abstract: Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise a vertebrate HMG A box, and an antibody preparation that specifically binds to a vertebrate HMG B box. The methods comprise treating a cell or a patient with sufficient amounts of the composition to inhibit the release of the proinflammatory cytokine, or to inhibit the inflammatory cytokine cascade.Type: ApplicationFiled: May 15, 2002Publication date: March 27, 2003Applicant: North Shore Long Island Jewish Research InstituteInventors: Kevin J. Tracey, Huan Yang, Howland Shaw Warren, Mitchell P. Fink
-
Patent number: 5423320Abstract: A method and apparatus for measuring or monitoring pCO.sub.2, and optionally pO.sub.2, on a real-time basis, in the stomach or the intestine using air tonometry. The intraluminal measurements are made using a catheter having a CO.sub.2 sensor, and optionally a pO.sub.2 sensor, at its tip for in situ measurements, or by circulating a fixed amount of air through the catheter with measurement occurring at the proximal end of the catheter. Instrumentation supporting the sensor may be adapted for location within a patient or external to a patient.Type: GrantFiled: April 20, 1993Date of Patent: June 13, 1995Assignee: Argus Critical Care, Inc.Inventors: Andrew L. Salzman, Mitchell P. Fink, Jeffrey B. Kane